This is reported by TASS with reference to the press service of the pharmaceutical company Uniao Quimica, which is a partner of the Russian Direct Investment Fund (RDIF).
“Cell material for the production of the Sputnik V vaccine has just been delivered to the Uniao Quimica facility in Brasilia,” the press service said in a statement.
Bolivia had previously registered the Sputnik V vaccine.